Evidence map›Paper›PMID 37370056›Full record

ArticleBMC neurology2023

Two rare cases of myelin oligodendrocyte glycoprotein antibody-associated disorder in children with leukodystrophy-like imaging findings.

Xin Wang, Ruibin Zhao, Huafang Yang, Chong Liu, Qing Zhao

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Movement Disorders in MOGAD: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026
    Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xin Wang *Second Department of Neurology, Hebei Children's Hospital, Shijiazhuang, China. xinbelieve2013@126.com.ORCID http://orcid.org/0000-0002-5407-3913
Ruibin Zhao *School of Medical Imaging, Hebei Medical University, Shijiazhuang, China.
Huafang YangSecond Department of Neurology, Hebei Children's Hospital, Shijiazhuang, China.
Chong LiuSecond Department of Neurology, Hebei Children's Hospital, Shijiazhuang, China.
Qing ZhaoSecond Department of Neurology, Hebei Children's Hospital, Shijiazhuang, China.
Hospital of Hebei Province · CNHebei Medical University · CN

Funding

Hebei Medical Science and Technology Research Project 20220723
6 · The paper itself

Abstract

backgroundChildren with acquired demyelinating syndromes (ADS) whose sera are positive for myelin oligodendrocyte glycoprotein (MOG) immunoglobulin (IgG) can be diagnosed with MOG-IgG associated disorder (MOGAD). Cases with leukodystrophy-like imaging findings with recurrent MOGAD have rarely been reported. CASE PRESENTATION: Two children with MOGAD, whose onset age was 6 months and 3 years, respectively, were admitted to the hospital due to fever and altered consciousness. In both children, MOG-IgG was detected in the serum using live cell-based assay. Brain magnetic resonance imaging (MRI) revealed leukodystrophy-like lesions with diffuse bilateral white matter. Cerebrospinal fluid (CSF) analysis showed mild pleocytosis with normal or slightly increased protein levels and no oligoclonal bands. Metabolic and inflammatory blood/CSF markers were all negative. Full exon gene testing revealed normal results, and nuclear and mitochondrial DNA were normal. Despite regular immunotherapy and reduction of lesions based on brain MRI results, the patients repeatedly relapsed and had residual neurological dysfunction at 3-4 years of follow-up.

conclusionsAlthough MOGAD is a monophasic and benign condition, certain MOGAD patients can experience multiple relapses and residual neurologic deficits. The spectrum of clinical manifestations in MOGAD is wider in children than in previously reported cases, including cases with leukodystrophy-like imaging findings. Such imaging findings along with MOG-IgG may occur recurrently and result in severe neurological prognosis. Patients with extensive and confluent white matter lesions should undergo early testing of MOG-IgG to ensure early therapy. In refractory cases, MOGAD treatment may need to be escalated beyond the current therapy, which means second-line immunotherapy should be performed as early as possible and hormone levels should not be rapidly reduced. Early diagnosis and appropriate treatment may improve the prognosis of children with MOGAD.

Indexed as

AutoantibodiesDemyelinating DiseasesBrainChildHumansImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinAutoantibodiesImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinAcquired demyelinating syndromesBrain magnetic resonance imagingChildrenLeukodystrophy-likeMyelin oligodendrocyte glycoprotein antibody-associated disorder

Identifiers

PMID37370056
PMCPMC10294490
OpenAlexW4382280614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.